A randomised controlled pilot trial of Argentum/Urtica comp. Gel for prevention and management of radiation dermatitis in breast cancer

Read full text Summarise with VIRAT
Authors: Freeman Jodie, Nannen Timo, Susanne Sester, Wolf Ursula
Cited by: 0
References: 21

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background Radiation dermatitis (RD) is a frequent adverse effect of breast cancer radiotherapy that can impair quality of life and disrupt treatment. Evidence supporting any single topical preventive intervention remains limited. Objective This pilot randomised controlled study explored whether Argentum/Urtica comp. Gel influences RD severity and patient-reported symptoms compared with standard skin care, and aimed to generate effect estimates for future trials. Methods Patients undergoing breast radiotherapy were randomised to Argentum/Urtica comp. Gel or standard care (Excipial-Hydrolotion). Outcomes included physician-assessed RD severity (extended CTCAE), rescue-care use, and patient-reported outcomes (VAS, Skindex-16, FACIT-TS-G). No adjustment for multiple testing was performed. Results Thirty patients were randomised; 28 were included in the primary analysis. No difference in maximum acute RD severity was observed (median CTCAE 1.7 in both groups). Rescue-care use was 31% (95% CI: 13–58%) in the Argentum/Urtica comp. Gel group and 69% (95% CI: 42–87%) in the standard-care group (χ² = 5.073, p = 0.020). Given the open-label design, clinician-driven escalation, small sample, and multiple testing, this finding should be interpreted cautiously and may reflect bias or chance. Trends toward lower pain and itch did not reach statistical significance. No relevant differences were observed in Skindex-16 or FACIT-TS-G. Conclusion The primary endpoint was not met. The observed difference in rescue-care use is exploratory and hypothesis-generating. Larger, blinded trials with predefined escalation criteria are required. Trial Registration NCT03494205 Register: Clinicaltrials.gov

Fields of Study & Subjects

Chemotherapy-related skin toxicity Effects of Radiation Exposure Dermatologic Treatments and Research

Publication details

Journal / source
Advances in Integrative Medicine
Volume
13
Issue
2
Pages
100650–100650
Publication date
25 March 2026
Language
EN